Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Subscribe To Our Newsletter & Stay Updated